Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2009-03-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
NCT05097716
A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects
NCT04804904
PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects
NCT03942666
A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants
NCT02541669
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
NCT06126562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pikamilone
No interventions assigned to this group
dosage
low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
No interventions assigned to this group
tablet
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* weight: BMI: 19-24
* written informed consent was finished.
Exclusion Criteria
* taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study.
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Sciences
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
shanghai institute of materia medica
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
D F Zhong, PH.D
Role: STUDY_CHAIR
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the second hospital to liaoning university of TCM
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SIMM-DMPK-080901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.